MOH — authorised 25 November 2019
- Marketing authorisation holder: GLOBAL BLOOD THERAPEUTICS INC
- Status: likely_approved
MOH authorised Oxbryta on 25 November 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 25 November 2019.
GLOBAL BLOOD THERAPEUTICS INC holds the Israeli marketing authorisation.